Gülşen Akman Demır1, Recai Türkoğlu2, Sabahattin Saıp3, Nur Yüceyar4, Hüsnü Efendı5, Ömer Faruk Turan6, Kadriye Ağan7, Murat Terzı8, Cavit Boz9, Aslı Tuncer10, Belgin Koçer11, Mithat Kasap12, Zeynep Çalişkan12. 1. Department of Neurology, İstanbul Bilim University School of Medicine, İstanbul, Turkey. 2. Department of Neurology, Haydarpaşa Numune Training Research Hospital, İstanbul, Turkey. 3. Department of Neurology, İstanbul University Cerrahpaşa School of Medicine, İstanbul, Turkey. 4. Department of Neurology, Ege University School of Medicine, İzmir, Turkey. 5. Department of Neurology, Kocaeli University School of Medicine, Kocaeli, Turkey. 6. Department of Neurology, Uludağ University School of Medicine, Bursa, Turkey. 7. Department of Neurology, Marmara University School of Medicine İstanbul, Turkey. 8. Department of Neurology, Ondokuz Mayıs University School of Medicine, Samsun, Turkey. 9. Department of Neurology, Karadeniz Teknik University School of Medicine, Trabzon, Turkey. 10. Department of Neurology, Hacettepe University School of Medicine, Ankara, Turkey. 11. Department of Neurology, Gazi University School of Medicine, Ankara, Turkey. 12. Department of Medical, Novartis Pharmaceuticals Turkey, İstanbul, Turkey.
Abstract
INTRODUCTION: To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents. METHODS: Patients aged 18-65 years with RRMS who fulfilled the eligibility criteria were enrolled from 16 centers throughout Turkey. Treatment Satisfaction Questionnaire for Medication and 36-item Short-Form Health Survey were completed at baseline and four visits to assess patient satisfaction and quality of life. RESULTS: Forty-two patients (62% male; mean age: 35.7±9.4 years) were eligible for inclusion. Patient satisfaction scores at the end of the study (44.7±9.9) were significantly higher than those at baseline [32.0±9.9; (p<0.001)]. The only significant increase in the quality of life survey was in the emotional aspect (p=0.019). There were 124 adverse events and none of the five serious adverse events noted was considered drug-related. CONCLUSION: Large-scale comparative studies performed with disease specific quality of life instruments will allow more information on this issue. Copyright:
INTRODUCTION: To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents. METHODS: Patients aged 18-65 years with RRMS who fulfilled the eligibility criteria were enrolled from 16 centers throughout Turkey. Treatment Satisfaction Questionnaire for Medication and 36-item Short-Form Health Survey were completed at baseline and four visits to assess patient satisfaction and quality of life. RESULTS: Forty-two patients (62% male; mean age: 35.7±9.4 years) were eligible for inclusion. Patient satisfaction scores at the end of the study (44.7±9.9) were significantly higher than those at baseline [32.0±9.9; (p<0.001)]. The only significant increase in the quality of life survey was in the emotional aspect (p=0.019). There were 124 adverse events and none of the five serious adverse events noted was considered drug-related. CONCLUSION: Large-scale comparative studies performed with disease specific quality of life instruments will allow more information on this issue. Copyright:
Authors: Peter A Calabresi; Ernst-Wilhelm Radue; Douglas Goodin; Douglas Jeffery; Kottil W Rammohan; Anthony T Reder; Timothy Vollmer; Mark A Agius; Ludwig Kappos; Tracy Stites; Bingbing Li; Linda Cappiello; Philipp von Rosenstiel; Fred D Lublin Journal: Lancet Neurol Date: 2014-03-28 Impact factor: 44.182
Authors: Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin Journal: N Engl J Med Date: 2010-01-20 Impact factor: 91.245
Authors: Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Bhupendra O Khatri; Xavier Montalban; Jean Pelletier; Ruggero Capra; Paolo Gallo; Guillermo Izquierdo; Klaus Tiel-Wilck; Ana de Vera; James Jin; Tracy Stites; Stacy Wu; Shreeram Aradhye; Ludwig Kappos Journal: N Engl J Med Date: 2010-01-20 Impact factor: 91.245
Authors: Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Guillermo Izquierdo; Bhupendra Khatri; Xavier Montalban; Jean Pelletier; Benjamin Eckert; Dieter A Häring; Gordon Francis Journal: J Neurol Date: 2013-04-30 Impact factor: 4.849
Authors: Fred Lublin; David H Miller; Mark S Freedman; Bruce A C Cree; Jerry S Wolinsky; Howard Weiner; Catherine Lubetzki; Hans-Peter Hartung; Xavier Montalban; Bernard M J Uitdehaag; Martin Merschhemke; Bingbing Li; Norman Putzki; Fonda C Liu; Dieter A Häring; Ludwig Kappos Journal: Lancet Date: 2016-01-28 Impact factor: 79.321
Authors: Ludwig Kappos; Paul O'Connor; Ernst-Wilhelm Radue; Chris Polman; Reinhard Hohlfeld; Krzysztof Selmaj; Shannon Ritter; Rolf Schlosshauer; Philipp von Rosenstiel; Lixin Zhang-Auberson; Gordon Francis Journal: Neurology Date: 2015-03-20 Impact factor: 9.910
Authors: Jonathan Calkwood; Bruce Cree; Heidi Crayton; Daniel Kantor; Brian Steingo; Luigi Barbato; Ron Hashmonay; Neetu Agashivala; Kevin McCague; Nadia Tenenbaum; Keith Edwards Journal: BMC Neurol Date: 2014-11-26 Impact factor: 2.474